Precision Medicine is a customised approach to medical management that considers which approaches will be most effective for an individual patient based on genetic, environmental, and lifestyle factors. Targeting diagnostic and treatment approaches to specific patients or groups of patients, improves treatment efficacy, whilst also reducing unwanted side-effects and cost. Such an approach is in contrast to traditional treatment and prevention strategies, which are developed based on population averages and broadly delivered regardless of patient differences.
Despite the benefits, adoption of new precision medicine technologies across the UK by the health services has been slow. This is due to an inadequate supply of clinical samples, skills shortages and an increased regulatory burden that presents a major barrier for market entry and international trade.
CALIN presents the opportunity for appropriate R&D to stimulate innovation and skilled personnel to take the lead in implementation of a formal diagnostic or therapeutic technology appraisal and adoption process.
CALIN Partners offering expertise in Precision Medicine include Bangor University, Tyndall National Institute, Cardiff University and University College Dublin.
Regenerative medicine is the process of replacing or regenerating previously irreparable human cells, tissues or organs to restore or establish their normal function. The field encompasses a range of disciplines including tissue engineering, gene therapy, molecular biology and biomedical engineering techniques.
Significant support is required to grow the existing regenerative medicine sector and capture external opportunities, which although currently very limited in scope, have the potential to be a high value area for growth.
Wales and Ireland have world-leading regenerative medicine research capabilities developing within academia and industry; but routes to commercialization are not clear.
The CALIN network allows the translation of regenerative medicine-related academic research into commercial products.
CALIN Partners offering expertise in in regenerative medicine are NUI Galway and Swansea University.
Biocompatibility and Safety Evaluation
Biocompatibility and Safety Evaluation explores the interaction of living systems or tissue with materials such as nanoparticles or nanostructured materials, to determine their biologically compatibility.
The nature of materials used in medical devices and any associated drugs have the potential to cause adverse reactions leading to local or systemic responses. Identifying potential reactions is crucial for the safe and sustainable development of life-science materials and technologies.
Furthermore, the level of industrial and research sector work in the field of nanomedicine and nanobiology is rapidly expanding. However, the development of accurate and informative safety evaluation protocols has lagged behind. CALIN can provide the expertise and technology to develop products and services that ensure safe and sustainable nanomaterial and nanotechnology innovations.
Research within this CALIN theme covers areas including nanosafety and toxicology screening. This can include the implementation and improvement of new safety evaluation programmes and protocols and testing materials in vitro and in vivo.
CALIN Partners offering expertise in biocompatibility and safety evaluation are Swansea University and University College Dublin.